VeraDermics Inc. is a dermatology pharmaceutical start-up, makers of WartPatch
Location: United States
Total raised: $225M
Investors 1
| Date | Name | Website |
| - | Connecticu... | ctinnovati... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.10.2025 | Series C | $150M | Viking Glo... |
| 14.12.2024 | Series B | $75M | - |
Mentions in press and media 9
| Date | Title | Description |
| 12.02.2026 | NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell | NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE P... |
| 04.02.2026 | NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA | NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pr... |
| 20.10.2025 | Veradermics: $150 Million Series C Raised For Advancing Late-Stage Trials Of VDPHL01 | Veradermics, a dermatologist-founded, late clinical-stage biopharmaceutical company developing first-in-class treatments for common dermatologic conditions, has announced the completion of an oversubscribed $150 million Series C financing r... |
| 14.12.2024 | Veradermics Secures $75 Million to Tackle Hair Loss Epidemic | In a world where appearances often dictate confidence, hair loss can feel like a thief in the night. It creeps in silently, leaving millions grappling with its emotional toll. Enter Veradermics, a New Haven-based biopharmaceutical company, ... |
| 14.12.2024 | Veradermics: $75 Million (Series B) Raised To Develop Therapeutics For Common Dermatologic Conditions | Veradermics – a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class therapeutics for common dermatologic conditions – announced the closing of a $75 million Series B financing. The fina... |
| 11.12.2024 | Veradermics Raises $75M in Series B Financing | Veradermics, a New Haven, CT-based clinical-stage aesthetics and dermatology-focused biopharmaceutical company, raised $75M in Series B funding. The round was led by Suvretta Capital Management and included new investors Longitude Capital, ... |
| 24.03.2023 | Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts | WEST HARTFORD, Conn. (PRWEB) March 24, 2023 Veradermics Inc., a clinical-stage medical dermatology company with a pipeline of first-in-class product candidates targeting highly prevalent skin conditions, today announced that it has commence... |
| 23.08.2022 | VeraDermics Inc. Secures Licensing of First-in-Class Antiviral Targeting the Treatment of Molluscum Contagiosum and other Poxviruses | WEST HARTFORD, Conn. (PRWEB) August 23, 2022 VeraDermics Incorporated, developer of drugs for dermatology, today announced that it has entered into a definitive license agreement with the University of Pennsylvania (Penn) for patent rights ... |
| - | VeraDermics | “Veradermics, Inc. is a medical dermatology company advancing first-in-class therapeutics that address real-world patient needs in under-innovated dermatology markets.” |